Health Trials

Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth

ConditionsTelogen EffluviumFemale Pattern Hair LossFemale Pattern Hair Loss, Androgenic AlopeciaMale Pattern BaldnessAndrogenetic AlopeciaAndrogenetic Alopecia (AGA)
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorApplied Biology, Inc.

About this trial

The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth

Eligibility criteria

Qualifiers

Age 18 or older

Diagnosed with telogen effluvium

Willing and able to apply the treatment as directed, comply with study

Otherwise healthy

Disqualifiers

A medical history that may interfere with study objectives

Women who are pregnant, lactating, or planning to become pregnant during the study period

Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)

Subjects who have known allergies to any excipient in DA-001

Trial design

Treatments tested in this trial

  • DA-001
  • Placebo
  • Phenylephrine
  • DA-001 Topical + DA-005 Oral (HIF-1α supplement)
  • DA-010 - Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)
  • Phenylephrine Topical 0.25% + Intact Pro Topical
  • Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement)

Treatment groups

1,120 Participants
are divided into 7 treatment groups

7

Treatment groups

See each treatment group below.

Locations

This trial has no locations

Sponsors and collaborators

Applied Biology, Inc.

Lead sponsor

Follea International Limited

Collaborator

Daniel Alain, Inc.

Collaborator

Source ClinicalTrials.gov